2nd & 3rd November 2022
Park Regis Hotel, Birmingham
This promotional meeting is organised and funded by Novartis Pharmaceuticals UK Limited and is intended for UK Healthcare professionals only.
UK | October 2022 | 245281
Adverse events should also be reported to Novartis via email@example.com or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about a product, please contact Medical Information on 01276 698370 or by email at firstname.lastname@example.org
To learn about your data privacy rights and the use of your personal information, we invite you to read our General Privacy Notice for Business Partners.
Indications: Treatment of: moderate to severe plaque psoriasis in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis in adults (alone or in combination with methotrexate) who have responded inadequately to disease-modifying anti-rheumatic drug therapy; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs.